Idecabtagene vicleucel (Abecma)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: A preparation of autologous peripheral blood T lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells.

Toxicity management

Diseases for which it is used

History of changes in FDA indication

  • 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (Approval based on KarMMa)

Patient Drug Information

Also known as

  • Code name: bb2121
  • Generic name: ide-cel
  • Brand name: Abecma